Stories
Aurobindo Pharma's Acrotech Enters US Dermatology Market with Adquey Launch
N
News18•30-09-2026, 22:45
Aurobindo Pharma's Acrotech Enters US Dermatology Market with Adquey Launch
- •Aurobindo Pharma's subsidiary Acrotech Biopharma launched Adquey ointment in the US, marking its entry into the American dermatology market.
- •Adquey is a non-steroidal topical treatment for mild-to-moderate atopic dermatitis in adults and pediatric patients aged two years and above.
- •The drug was originally discovered by Otsuka Pharmaceutical and licensed to Acrotech Biopharma for commercialization in the United States.
- •A dedicated dermatology business unit has been established to support the launch and expand this therapeutic segment.
- •The market for this product is estimated at around USD 1.3 billion for the 12 months ending July 2026, according to IQVIA MAT data.
Key Questions Answered
Acrotech Biopharma launched the Adquey ointment, which is a non-steroidal topical treatment for mild-to-moderate atopic dermatitis in adults and pediatric patients aged two years and above.
The drug was originally discovered by Otsuka Pharmaceutical and subsequently licensed to Acrotech Biopharma for commercialization in the United States.
According to IQVIA MAT data for the 12 months ending July 2026, the product will compete in a market estimated at around USD 1.3 billion.
